Impala vs EchoNext

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 75/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.

Impala

by AliveCor

EchoNext

by Pathway Labs

AI Verdict

Impala is a portable 12-lead ECG *device* that acquires and generates ECGs, with AI to detect life-threatening cardiac conditions like heart attacks. EchoNext is an AI *tool* that analyzes standard 12-lead ECGs (which could be acquired by a device like Impala) to detect hidden structural heart disease, including heart failure and valve disease. While both are cardiology AI tools utilizing ECGs, Impala focuses on ECG acquisition and initial cardiac determinations, whereas EchoNext specializes in advanced AI-driven interpretation of existing ECGs for a broader range of structural heart conditions.

Choose Impala if…

Choose Impala if you are a healthcare professional needing a portable, AI-powered 12-Lead ECG for rapid cardiac assessment in diverse settings, such as physician offices, minute clinics, or remote locations. Its reduced leadset and single cable simplify placement, making it ideal for situations where traditional 10-electrode ECGs are impractical due to cost, size, or the need for specialized clinicians. This tool is particularly well-suited for detecting life-threatening cardiac conditions, including heart attacks and various arrhythmias and morphologies, with its FDA-cleared AI technology.

View Impala →

Choose EchoNext if…

Choose EchoNext if you need an AI tool to analyze standard ECGs for the detection of hidden structural heart disease, including heart failure, valve disease, and pulmonary hypertension. This tool is designed to bridge the gap in early detection of cardiovascular disease by identifying patients who should proceed to an echocardiogram, even when symptoms are not yet present. It is ideal for broad access in various clinical settings, from major hospitals to community practices, and integrates with clinical decision support platforms like OpenEvidence.

View EchoNext →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature	Impala	EchoNext
Pricing	Contact for pricing	Starts at $600/month
Deployment	Portable device, integrated with mobile applications/platforms.	Available through the OpenEvidence clinical decision support platform.
BAA Available	Unknown	Yes AI-estimated
FDA Status	1 AI-estimated	Yes AI-estimated
HIPAA	Unknown	Yes AI-estimated

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

Impala

Impala (Tool A) appears to have a stronger focus on user experience due to its portable design, reduced leadset for easier placement, and simplified single-cable design, which minimizes training and patient discomfort. EchoNext (Tool B) is deployed through a platform, which may introduce an additional layer of complexity for new users.

Clinical Value

EchoNext

EchoNext (Tool B) demonstrates superior clinical value by detecting a broader range of hidden structural heart diseases (heart failure, valve disease, pulmonary hypertension, severe hypertrophy) from standard ECGs, and has shown higher accuracy than cardiologists in studies. Impala (Tool A) focuses on 12-lead ECG acquisition and detection of life-threatening cardiac conditions, including heart attacks, but doesn't specify the breadth of structural heart disease detection.

Pricing & Value

EchoNext

EchoNext (Tool B) offers transparent tiered pricing starting at $600/month, with options for different organizational sizes and potential annual discounts. Impala (Tool A) requires contacting for pricing, making its value proposition less clear upfront. While Impala's portability offers value, EchoNext's clear pricing and broad detection capabilities present a more defined value.

Enterprise Readiness

EchoNext

EchoNext (Tool B) is designed for broad access, from major hospitals to community practices, and is available through the OpenEvidence clinical decision support platform, which is used by a large number of US physicians. This suggests a strong focus on integration and scalability within existing healthcare workflows. Impala (Tool A) is a portable device integrated with mobile applications, which is enterprise-ready but may require more direct management of devices.

Innovation

EchoNext

EchoNext (Tool B) represents a significant innovation as the world's first FDA-approved AI detection tool to analyze standard ECGs for multiple structural heart diseases, including conditions previously imperceptible to the human eye. This breakthrough has led to the first peer-reviewed heart transplant attributable to AI-based disease detection. Impala (Tool A) is innovative in its portable 12-lead ECG acquisition with a reduced leadset, but EchoNext's diagnostic capabilities from a standard ECG appear to be a more substantial leap in AI diagnostics.

Support & Docs

Tie

Both companies are FDA-cleared, implying a certain level of documentation and regulatory support. However, specific details regarding ongoing customer support, comprehensive documentation, or user communities for either Impala or EchoNext are not extensively provided in the given information or readily available through general web searches. AliveCor's Kardia devices have mixed customer reviews regarding support, but this may not directly reflect Impala.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature	Impala	EchoNext
Name	Impala	EchoNext
Company	AliveCor	Pathway Labs
Description	A portable, AI-powered 12-Lead ECG device for healthcare professionals.	An FDA-cleared AI tool that analyzes standard ECGs to detect hidden structural heart disease.
Key Features	Portable 12-Lead ECG acquisition, AI technology (KAIu2122 12L) for cardiac determinations, detects life-threatening cardiac conditions, reduced leadset for easier placement.	AI-powered ECG analysis, detection of hidden structural heart disease, identifies heart failure risk, screens for valve disease, detects pulmonary hypertension indicators, utilizes standard 12-lead ECGs.

Videos

Demos, reviews, and walkthroughs featuring Impala and EchoNext.

Loading videos…

Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

How do these tools integrate into existing clinical workflows for ECG acquisition and analysis?

Impala is a portable 12-Lead ECG device that integrates with mobile applications and platforms, and AliveCor offers EHR integration, SDK, and API solutions to seamlessly pull ECG data into existing EHR systems, including partnerships with systems like GE Healthcare's MUSEu2122 NX. EchoNext integrates through the OpenEvidence clinical decision support platform and analyzes standard ECGs, meaning it can be incorporated into workflows where standard 12-lead ECGs are already being performed.

What is the depth of EHR integration for each tool, and how does it support data flow and clinical decision-making?

AliveCor's Impala offers EHR integration, SDK, and API solutions to automatically pull ECGs into EHR systems, allowing for seamless integration of cardiac patient data and enabling deeper analysis with its FDA-cleared algorithms that detect up to 35 rhythms and morphologies. EchoNext is available through the OpenEvidence platform, which is used by over half of US clinicians, suggesting a streamlined pathway for integrating its AI-powered ECG analysis into clinical decision support.

What is the accuracy and sensitivity of each tool in detecting cardiac conditions?

Impala utilizes AI technology (KAIu2122 12L) to detect life-threatening cardiac conditions, including heart attacks, and its FDA-cleared algorithms can detect up to 35 rhythms and morphologies. EchoNext, trained on over 700,000 ECG-echocardiogram pairs, demonstrated higher accuracy (77%) in identifying structural heart problems compared to cardiologists (64%) and even cardiologists with AI assistance (69%) in a study involving 3,200 ECGs. It has also shown high accuracy with an AUROC of 85% in internal tests and 78-80% in external validation.

Which specialties are these tools best suited for, and what specific clinical problems do they address?

Impala is designed for Cardiology and Emergency Medicine, focusing on rapid cardiac assessment and the detection of life-threatening cardiac conditions, including heart attacks, using a portable 12-Lead ECG. EchoNext is suitable for Cardiology, Family Medicine, Hospital Medicine, and Internal Medicine, specializing in the detection of hidden structural heart disease, including heart failure, valve disease, and pulmonary hypertension, from standard ECGs.

What kind of audit-trail features are available to track the use and impact of these tools in clinical practice?

While specific audit-trail features for Impala are not detailed, AliveCor emphasizes seamless integration with existing workflows for healthcare professionals, which would typically necessitate some form of usage tracking for accountability and analysis. For EchoNext, its integration into the OpenEvidence platform suggests that audit trails would likely be managed through that system, as EHR audit logs are a valid source for clinical workflow analysis and can provide an objective view of clinician behaviors.

How do these tools support multi-site rollout and what considerations should be made for larger healthcare systems?

AliveCor's Impala, with its portable nature and EHR integration capabilities, can support multi-site rollouts by providing consistent ECG acquisition and data flow across different locations. AliveCor has also seen adoption in over 250 U.S. practices and has clinical integration sprints focused on hospital integrations, such as with GE HealthCare MUSE. EchoNext's availability through the OpenEvidence platform, which is used by over half of US clinicians, indicates a scalable deployment model suitable for broad access across major hospitals and community practices.

What clinical context should a physician consider when choosing between Impala and EchoNext?

Physicians should consider that Impala is a portable 12-Lead ECG device for immediate, AI-powered cardiac rhythm and morphology determinations, including acute events like heart attacks. EchoNext, on the other hand, is an AI analysis tool for *existing* standard ECGs, focused on detecting hidden structural heart diseases like heart failure, valve disease, and pulmonary hypertension, which might otherwise go undetected until symptomatic. The choice depends on whether the primary need is for a portable ECG acquisition device with immediate AI interpretation (Impala) or an AI-powered screening tool for deeper analysis of standard ECGs to identify underlying structural heart disease (EchoNext).

More Comparisons

Assert-IQ vs Rapid Enterprise Platform

AISAP Cardio vs Rapid Enterprise Platform

AngioWaveNet vs Rapid Enterprise Platform

CorVista System with PH Add-On vs Rapid Enterprise Platform

More matchups featuring Impala or EchoNext

Backers

Who funded each tool's parent company.